Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

This study is testing a new targeted drug called BEBT-109 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a specific mutation called an EGFR exon 20 insertion — a mutation that many standard EGFR-targeting drugs don't work against. **You may be eligible if...** - You are 18 or older - You have confirmed advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation - You have already received at least one prior chemotherapy regimen and it either stopped working or you couldn't tolerate it - You are in acceptable overall health condition **You may NOT be eligible if...** - You have not yet tried standard chemotherapy - You have other types of EGFR mutations (not exon 20 insertion) - Your overall health would make this treatment unsafe Talk to your doctor to see if this trial is right for you.